伊波拉出血热药物和疫苗市场报告：趋势、预测和竞争分析（至 2031 年）

全球伊波拉出血热药物和疫苗市场前景看好，医院和诊所市场以及门诊手术中心市场都存在机会。预计到 2031 年全球伊波拉出血热药物和疫苗市场规模将达到 2.17 亿美元，2025 年至 2031 年的复合年增长率为 28.6%。该市场的主要驱动力是日益严重的感染疾病以及政府支持伊波拉研究和伊波拉出血热治疗及疫苗开发的措施。

• Lucintel 预测，在预测期内，萨伊的病毒株类型将出现最高的增长。
• 按地区划分，由于通用感染疾病爆发的发生率不断增加、先进医疗技术的采用不断增加以及该地区拥有完善的医疗保健基础设施，北美将继续成为最大的地区。

伊波拉出血热药物和疫苗市场的策略性成长机会

伊波拉出血热治疗和疫苗市场提供了多种成长机会，特别是在药物开发、製造和分销领域。疾病爆发期间对更快、更有效干预的需求正在推动这一市场的发展。以下是按应用程式分類的五个关键成长机会：

• 扩展mRNA疫苗平台：伊波拉疫苗研发中采用的mRNA技术是一个主要的扩展领域。 mRNA 技术在 COVID-19 中的成功应用可能有望应用于伊波拉疫苗的生产和分发，这可能会彻底改变疫情应变的局面。
• 高风险地区的本地生产疫苗：在西非等伊波拉出血热疫情多发地区投资疫苗生产设施可能会带来巨大的成长。本地生产可以减少对全球供应链的依赖，同时缩短反应时间并提高区域的准备和復原力。
• 多病原疫苗的开发：设计能够预防多种病原体（包括伊波拉病毒感染疾病(EVD)）的免疫原也是一种越来越流行的方法。这将改善针对不同感染疾病的疫苗接种活动的协调，并实现更广泛和有效的预防。
• 合作推动全球卫生倡议：透过联合政府、非政府组织和製药公司，我们可以在全球扩大疫苗研究、开发和交付。此类伙伴关係可以汇集和提供治疗病毒性出血热患者创新抗体介入所需的资源。
• 抗体治疗的进展：单株抗体疗法作为伊波拉病毒疾病的治疗选择还有很长的路要走，但对于未来的发展和商业性开发来说是一个有吸引力的途径。抗体疗法可以为高风险族群提供即时保护，同时提高已感染者的存活率，并补充疫苗宣传活动。

透过推动创新、提高製造能力和扩大全球影响力，这些策略成长领域有可能改变伊波拉出血热治疗和疫苗市场的格局。结果很可能是对下一次伊波拉出血热疫情做出更有力、更有效的应对。

伊波拉出血热药物和疫苗市场驱动因素和挑战

多种市场驱动因素和挑战影响伊波拉出血热药物和疫苗市场的发展和成长。其中包括技术进步、经济方面和监管考虑。该市场有五个关键驱动因素和三个关键挑战：

推动伊波拉出血热药物和疫苗市场发展的因素如下：

• 疫苗开发的技术革命：mRNA和病毒载体平台等疫苗技术的进步正在推动开发更有效、更快的伊波拉疫苗。这些进展对于加强世界应对伊波拉出血热疫情的能力至关重要。
• 增加政府和世界卫生组织的支持：各国政府和世界卫生组织正在大力投资伊波拉出血热研究和疫苗开发。这种支持对于推进临床试验、获得必要的监管核准以及广泛分发疫苗至关重要。
• 预防性医疗保健需求增加：对伊波拉出血热潜在影响的认识不断提高，带来了对疫苗等预防措施的需求。这种需求正在推动市场发展，尤其是在易受伊波拉出血热疫情影响的高风险地区。
• 疫苗生产能力的扩大：市场的主要驱动力之一是全球疫苗生产的扩张，尤其是在非洲。本地生产将使我们能够更快地做出反应，减少对外部供应的依赖，更容易为未来的疫情做好准备。
• 官民合作关係与协作：公共部门与私部门合作可以促进伊波拉出血热治疗和疫苗市场的创新。此类合作有助于汇集资源、技能和资金，从而加快药物和疫苗的开发进程。

伊波拉出血热治疗和疫苗市场面临的挑战包括：

• 监管障碍和核准延迟：在复杂的监管环境中寻求解决方案可能会很困难，从而导致伊波拉出血热新药和疫苗的核准和分发延迟。因此，一旦疫情爆发，这种延误可能会阻碍国际社会采取应对措施。
• 供应链和分销挑战：将药品和疫苗运送到基础设施薄弱的偏远地区仍然存在问题。低温运输物流和运输问题可能会阻碍及时获得救命的治疗。
• 疫苗厌恶和公众认知：由于错误讯息和不信任导致的疫苗犹豫阻碍了疫苗接种。必须解决大众对伊波拉疫苗的认识和接受度问题，疫苗接种宣传活动才能成功。

伊波拉出血热药物和疫苗市场中有效治疗方法的开发和分发所固有的复杂性因其关键驱动因素和挑战而凸显。技术创新和全球合作改变了格局，但在这些突破成为现实之前必须克服监管和物流障碍。

目录

第一章执行摘要

第 2 章全球伊波拉出血热药物与疫苗市场：市场动态

• 简介、背景和分类
• 供应链
• 产业驱动因素与挑战

第 3 章 市场趋势与预测分析（2019-2031）

• 宏观经济趋势（2019-2024）与预测（2025-2031）
• 全球伊波拉出血热药物与疫苗市场趋势（2019-2024 年）及预测（2025-2031 年）
• 全球伊波拉出血热药物和疫苗市场（以新药类型）
  • Zmapp
  • Favipiravir
  • Gs-5734
  • Tkm-Ebola
  • Avi-7537
• 全球伊波拉出血热药物和疫苗市场（按疫苗类型）
  • Cad3-Zebov
  • Rvsv-Zebov
  • 其他的
• 全球伊波拉出血热药物和疫苗市场（按病毒株类型）
  • 萨伊
  • 苏丹
  • 泰式森林
  • 雷斯顿
  • 本迪布焦病毒
• 全球伊波拉出血热药物和疫苗市场（按最终用途划分）
  • 医院和诊所
  • 门诊手术中心
  • 其他的

第 4 章区域市场趋势与预测分析（2019-2031 年）

• 全球伊波拉出血热药物和疫苗市场（按地区）
• 北美伊波拉出血热药物和疫苗市场
• 欧洲伊波拉出血热药物和疫苗市场
• 亚太伊波拉出血热药物与疫苗市场
• 世界其他地区的伊波拉出血热药物和疫苗市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 全球伊波拉出血热药物和疫苗市场按新药类型分類的成长机会
  • 全球伊波拉出血热药物和疫苗市场成长机会（按疫苗类型）
  • 全球伊波拉出血热药物和疫苗市场成长机会（按病毒株类型）
  • 全球伊波拉出血热药物和疫苗市场成长机会（按最终用途划分）
  • 全球伊波拉出血热药物和疫苗市场各区域成长机会
• 全球伊波拉出血热药物及疫苗市场新趋势
• 战略分析
  • 新产品开发
  • 全球伊波拉出血热治疗及疫苗市场产能扩大
  • 全球伊波拉出血热药物和疫苗市场的企业合併
  • 认证和许可

第七章主要企业简介

• Arbutus Biopharma
• GlaxoSmithKline
• Johnson & Johnson Services
• Hemispherx Biopharma
• BioCryst Pharmaceuticals
• NanoViricides
• NewLink Genetics

The future of the global Ebola drug and vaccine market looks promising with opportunities in the hospital & clinic and ambulatory surgical center markets. The global Ebola drug and vaccine market is expected to reach an estimated $217 million by 2031 with a CAGR of 28.6% from 2025 to 2031. The major drivers for this market are the growing prevalence of infectious diseases and supportive government initiatives toward Ebola research and the development of Ebola drugs and vaccines.

• Lucintel forecasts that, within the strain type category, zaire is expected to witness the highest growth over the forecast period.
• In terms of regions, North America will remain the largest region due to the growing prevalence of zoonotic diseases, the rising adoption of advanced medical technologies, and the presence of well-established healthcare infrastructure in the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Ebola Drug and Vaccine Market

The Ebola drug and vaccine market is a fast-changing environment where new technologies, partnerships, and regulatory frameworks are emerging to deal with the virus more effectively. These trends show a growing focus on global health security and innovation. Here are five key trends changing this market:

• Increased Emphasis on mRNA Vaccine Technology: The success of mRNA vaccines in COVID-19 has generated interest in using similar technology against Ebola. Companies are exploring mRNA platforms for faster and better vaccines. This could change how quickly new vaccines come to market during outbreaks.
• Scaling Up Global Vaccine Manufacturing Capacity: There is a strong move to expand vaccine manufacturing capacity globally, especially in Africa, to meet global demand. Local production minimizes dependence on imports and increases response time during outbreaks, improving preparedness and equitable distribution of the vaccine.
• Development of Therapeutic Antibodies: Monoclonal antibodies are being explored as an option for Ebola therapy, implying targeted treatment. This helps fill gaps left by vaccines by offering immediate protection and treatment options, particularly for those already infected or at high risk.
• Strengthening Global Health Partnerships: Public-private partnerships have become common, with government, non-governmental organizations, and pharmaceutical companies collaborating to drive innovation and access. These resources facilitate the mobilization of resources to hasten the development and dissemination of Ebola vaccinations and medications.
• Regulatory Harmonization and Fast-Track Approvals: Regulatory agencies are increasingly working together to harmonize standards and fast-track approvals for Ebola drugs and vaccines. Safe treatments reaching markets faster during emergencies enhance global health response efforts, making this an important trend.

These trends are thus collectively reshaping the Ebola drug and vaccine market, driving innovation, expanding access, and enhancing global preparedness. As they continue to evolve, these trends will likely result in more effective and equitable responses to managing Ebola outbreaks around the world.

Recent Developments in the Ebola Drug and Vaccine Market

The Ebola drug and vaccine market has experienced several significant developments aimed at ensuring global preparedness and response to the virus. These include new drug approvals and strategic alliances, among others. Here are five key developments that have major implications for the market:

• FDA Approval of Inmazeb: As the first-line treatment for Ebola, the FDA has approved Regeneron's Inmazeb, a combination of three monoclonal antibodies. The approval signifies an important milestone toward the provision of effective therapies for infected individuals, potentially lowering death tolls in subsequent outbreaks.
• WHO Prequalification of Johnson & Johnson's Zabdeno/Mvabea: The World Health Organization has prequalified Johnson & Johnson's two-shot Ebola vaccine regimen, known as Zabdeno/Mvabea, for emergency use. This move enhances global uptake of the vaccine, especially in areas with poor healthcare infrastructure, improving preventive measures against Ebola.
• Expansion of Manufacturing Facilities in Africa: Several pharmaceutical firms have announced intentions to establish vaccine manufacturing plants within Africa to increase local production during outbreaks, which will be much faster than relying on foreign suppliers when urgent distribution is needed.
• Strategic Collaboration Between GAVI and CEPI: The partnership between GAVI, The Vaccine Alliance, and the Coalition for Epidemic Preparedness Innovations (CEPI) has been strengthened to facilitate the development and equitable distribution of vaccines against Ebola disease. Therefore, this cooperation is essential for rapidly reaching at-risk populations through vaccination interventions.

By improving therapy options while expanding access and upgrading manufacturing capabilities, these developments are expected to have a significant impact on the Ebola drug and vaccine market. Combined, they create conditions for more effective global responses to future outbreaks of Ebola.

Strategic Growth Opportunities for Ebola Drug and Vaccine Market

The Ebola drug and vaccine market has several growth opportunities, particularly in the areas of drug development, manufacturing, and distribution. The demand for faster and more effective interventions during disease outbreaks drives these openings. Here are five significant opportunities for growth by application:

• Expanding mRNA Vaccine Platforms: mRNA technologies used to develop Ebola vaccines represent a major area of expansion. The successful use of mRNA technology during COVID-19 has opened up the possibility of its application in Ebola vaccine production and dissemination, which may be game-changing for responses during outbreaks.
• Locally Produced Vaccines in High-Risk Areas: Investing in vaccine production facilities within regions like West Africa that are prone to Ebola outbreaks can result in massive growth. Local manufacturing reduces reliance on global supply chains while hastening reaction times, thereby improving regional preparedness and resilience.
• Development of Multi-Pathogen Vaccines: One increasingly popular approach involves designing immunogens capable of protecting against multiple pathogens, including Ebola virus disease (EVD). This could improve coordination between immunization efforts targeted at different infectious diseases, offering broader protection with greater efficiency.
• Collaboration for Global Health Initiatives: Collaborations between governments, NGOs, and pharmaceutical companies can scale up vaccine R&D and delivery mechanisms worldwide. Such partnerships can pool the resources needed for innovative measures regarding therapeutic antibodies for treating patients with viral hemorrhagic fever, leading to greater accessibility.
• Progress in Therapeutic Antibody Treatment: Monoclonal antibody therapeutics as treatment options for EVD have a long way to go but still represent an attractive avenue for future developments and commercial exploitation. They can provide immediate protection to high-risk population groups while increasing survival rates among those already infected, complementing vaccination campaigns.

By fostering innovation, increasing manufacturing capabilities, and expanding global reach, these strategic growth areas could change the landscape of the Ebola drug and vaccine market. Consequently, they would likely lead to a much stronger and more effective response to the next outbreak of Ebola.

Ebola Drug and Vaccine Market Driver and Challenges

Several drivers and challenges influence the development and growth of the Ebola drug and vaccine market. These encompass technological advances, economic aspects, and regulatory considerations. There are five major drivers and three key challenges that affect this market.

The factors driving the Ebola drug and vaccine market include:

• Technological Revolution for Vaccine Development: Progress in vaccine technology, such as mRNA or viral vector platforms, has led to faster-acting Ebola vaccines that are more efficient. These developments are vital for enhancing global capacities to manage outbreaks.
• Increasing Government and Global Health Organization Support: Governments and global health organizations are investing heavily in Ebola research and vaccine development. This backing is fundamental for moving clinical trials forward, acquiring necessary approvals from regulators, and ensuring widespread distribution of vaccines.
• Rising Demand for Preventive Healthcare: The rising awareness of Ebola's potential impact has generated demand for preventive measures, such as vaccines. This demand drives the market, especially in high-risk areas where outbreaks of Ebola are more likely.
• Expansion of Vaccine Manufacturing Capabilities: One important driver in the market is the growth of vaccine manufacturing worldwide, particularly across Africa. Localized production provides quicker response times and reduces dependence on external supplies, making it easier to prepare for future outbreaks.
• Public-Private Partnerships and Collaborations: The public sector working jointly with the private sector facilitates access to innovation within the Ebola drug and vaccine market. These collaborations help pool resources, skills, and finances, thereby speeding up drug and vaccine development processes.

Challenges in the Ebola drug and vaccine market include:

• Regulatory Hurdles and Approval Delays: Navigating a complex regulatory landscape can be challenging, resulting in delays in the approval or distribution of new drugs or vaccines against Ebola. Consequently, these delays can hinder international responses to an outbreak.
• Supply Chain and Distribution Challenges: Transporting medicines and vaccines to remote areas lacking sufficient infrastructure remains problematic. Issues related to cold chain logistics and transportation can hinder timely access to life-saving treatments.
• Vaccine Hesitancy and Public Perception: Widespread immunization is impeded by vaccine hesitancy driven by misinformation and mistrust. To ensure successful vaccination campaigns, public perception and acceptance of Ebola vaccines must be addressed.

The complexities inherent in the development and distribution of effective treatments for the Ebola drug and vaccine market are illuminated by its major drivers and challenges. Although technological innovation and global collaboration have transformed this situation, it is necessary to overcome regulatory and logistical impediments for these breakthroughs to become reality.

List of Ebola Drug and Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies Ebola drug and vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the Ebola drug and vaccine companies profiled in this report include-

• Arbutus Biopharma
• GlaxoSmithKline
• Johnson & Johnson Services
• Hemispherx Biopharma
• BioCryst Pharmaceuticals
• NanoViricides
• NewLink Genetics

Ebola Drug and Vaccine by Segment

The study includes a forecast for the global Ebola drug and vaccine market by novel drug type, vaccine type, strain type, end use, and region.

Ebola Drug and Vaccine Market by Novel Drug Type [Analysis by Value from 2019 to 2031]:

• Zmapp
• Favipiravir
• Gs-5734
• Tkm-Ebola
• Avi-7537

Ebola Drug and Vaccine Market by Vaccine Type [Analysis by Value from 2019 to 2031]:

• Cad3-Zebov
• Rvsv-Zebov
• Others

Ebola Drug and Vaccine Market by Strain Type [Analysis by Value from 2019 to 2031]:

• Zaire
• Sudan
• Tai Forest
• Reston
• Bundibugyo Virus

Ebola Drug and Vaccine Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Ebola Drug and Vaccine Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Ebola Drug and Vaccine Market

The Ebola drug and vaccine market has experienced significant advancements driven by global efforts to combat the deadly virus. With ongoing outbreaks and the potential for future epidemics, governments and pharmaceutical companies are intensifying their research and development efforts. This has led to accelerated approvals, increased funding, and the introduction of new therapies and vaccines. Key countries like the United States, China, Germany, India, and Japan are at the forefront of these developments.

• United States: The U.S. has been a leader in Ebola research, with recent developments including FDA approval for the Ervebo vaccine and deployment of monoclonal antibody treatments like Inmazeb. Moreover, the government continues to fund research for next-generation vaccines and therapeutics that will ensure preparedness for potential outbreaks while enhancing global health security.
• China: By partnering with African nations and international organizations, China has increased its focus on Ebola. Recent developments include approval of the Ad5-EBOV vaccine developed by CanSino Biologics, which is part of a broader strategy to enhance its influence in global health matters and support pandemic preparedness initiatives.
• Germany: As part of its commitment to the global healthcare industry, developmental efforts toward Ebola are ongoing. Recent developments involve collaborations with international organizations aimed at developing new vaccine candidates and treatments. Additionally, Germany is supporting African nations by funding them and providing technical assistance to strengthen their healthcare systems and response capacities.
• India: India is emerging as a major manufacturer of Ebola vaccines. Recent developments include Bharat Biotech's efforts to scale up production capabilities to manufacture these vaccines on a large scale. At the same time, the nation's pharmaceutical sector produces generic versions of Ebola treatments, making them more affordable for developing countries.
• Japan: Japan is focused on innovative ways to treat or prevent the spread of Ebola. Recent developments include the discovery of new antiviral drugs and the creation of rapid diagnostic tools. Finally, Japan's commitment to global health is demonstrated through its contributions to international research collaborations and funding for vaccine development.

Features of the Global Ebola Drug and Vaccine Market

Market Size Estimates: Ebola drug and vaccine market size estimation in terms of value ($M).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Ebola drug and vaccine market size by various segments, such as by novel drug type, vaccine type, strain type, end use, and region in terms of ($M).

Regional Analysis: Ebola drug and vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different novel drug types, vaccine types, strain types, end uses, and regions for the Ebola drug and vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the Ebola drug and vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the Ebola drug and vaccine market by novel drug type (zmapp, favipiravir, gs-5734, tkm-Ebola, and avi-7537), vaccine type (cad3-zebov, rvsv-zebov, and others), strain type (zaire, sudan, tai forest, reston, and bundibugyo virus), end use (hospitals & clinics, ambulatory surgical centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Ebola Drug and Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Ebola Drug and Vaccine Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Ebola Drug and Vaccine Market by Novel Drug Type
  • 3.3.1: Zmapp
  • 3.3.2: Favipiravir
  • 3.3.3: Gs-5734
  • 3.3.4: Tkm-Ebola
  • 3.3.5: Avi-7537
• 3.4: Global Ebola Drug and Vaccine Market by Vaccine Type
  • 3.4.1: Cad3-Zebov
  • 3.4.2: Rvsv-Zebov
  • 3.4.3: Others
• 3.5: Global Ebola Drug and Vaccine Market by Strain Type
  • 3.5.1: Zaire
  • 3.5.2: Sudan
  • 3.5.3: Tai Forest
  • 3.5.4: Reston
  • 3.5.5: Bundibugyo Virus
• 3.6: Global Ebola Drug and Vaccine Market by End Use
  • 3.6.1: Hospitals & Clinics
  • 3.6.2: Ambulatory Surgical Centers
  • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Ebola Drug and Vaccine Market by Region
• 4.2: North American Ebola Drug and Vaccine Market
  • 4.2.1: North American Market by Strain Type: Zaire, Sudan, Tai Forest, Reston, and Bundibugyo Virus
  • 4.2.2: North American Market by End Use: Hospitals & Clinics, Ambulatory Surgical Centers, and Others
• 4.3: European Ebola Drug and Vaccine Market
  • 4.3.1: European Market by Strain Type: Zaire, Sudan, Tai Forest, Reston, and Bundibugyo Virus
  • 4.3.2: European Market by End Use: Hospitals & Clinics, Ambulatory Surgical Centers, and Others
• 4.4: APAC Ebola Drug and Vaccine Market
  • 4.4.1: APAC Market by Strain Type: Zaire, Sudan, Tai Forest, Reston, and Bundibugyo Virus
  • 4.4.2: APAC Market by End Use: Hospitals & Clinics, Ambulatory Surgical Centers, and Others
• 4.5: ROW Ebola Drug and Vaccine Market
  • 4.5.1: ROW Market by Strain Type: Zaire, Sudan, Tai Forest, Reston, and Bundibugyo Virus
  • 4.5.2: ROW Market by End Use: Hospitals & Clinics, Ambulatory Surgical Centers, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Ebola Drug and Vaccine Market by Novel Drug Type
  • 6.1.2: Growth Opportunities for the Global Ebola Drug and Vaccine Market by Vaccine Type
  • 6.1.3: Growth Opportunities for the Global Ebola Drug and Vaccine Market by Strain Type
  • 6.1.4: Growth Opportunities for the Global Ebola Drug and Vaccine Market by End Use
  • 6.1.5: Growth Opportunities for the Global Ebola Drug and Vaccine Market by Region
• 6.2: Emerging Trends in the Global Ebola Drug and Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Ebola Drug and Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Ebola Drug and Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Arbutus Biopharma
• 7.2: GlaxoSmithKline
• 7.3: Johnson & Johnson Services
• 7.4: Hemispherx Biopharma
• 7.5: BioCryst Pharmaceuticals
• 7.6: NanoViricides
• 7.7: NewLink Genetics